• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经母细胞瘤中的5' 扩增:一例报告。

5' Amplification in Neuroblastoma: A Case Report.

作者信息

Akhavanfard Sara, Nohr Erik, AlNajjar Mohammad, Haughn Mollie, Hashimoto Sayaka, Deeg Carol, Pfau Ruthann, Brundler Marie-Anne, Reshmi Shalini C

机构信息

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.

Department of Pathology and Laboratory Medicine, Alberta Children's Hospital, Calgary, Alberta, Canada.

出版信息

Case Rep Oncol. 2021 Mar 23;14(1):585-591. doi: 10.1159/000512187. eCollection 2021 Jan-Apr.

DOI:10.1159/000512187
PMID:33976638
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8077488/
Abstract

Neuroblastoma is the most common cancer in infants younger than 12 months of age, occurring with an incidence of 1 in 100,000 children. The clinical outcome of neuroblastoma ranges from spontaneous regression to treatment-resistant progression and/or metastasis, and accounts for 8-10% of childhood cancer deaths. Segmental chromosomal aberrations, as well as and amplification, are among factors contributing to an unfavorable genomic profile and high-risk disease classification. Here, we describe a 5-year-old male who presented with a large right renal neuroblastoma tumor having lung and liver metastases. Fluorescence in situ hybridization analysis indicated the presence of >20 copies of the 5' region of the gene in 26% of cells examined. Subsequent copy number assessment did not confirm amplification, but revealed a gain of exons 2-5 of , consistent with increased copy number for the 5' region of the gene. Subsequent array analysis showed the presence of other unfavorable prognostic genomic features, including segmental gain of the 17q region and amplification of the long arm of chromosome 12 harboring and both reported to be poor prognostic indicators in patients with atypical clinical features in neuroblastoma. Taken together, this report illustrates the importance of careful interpretation of aberrant FISH findings and subsequent use of orthogonal methods to clarify the presence of genomic alterations to successfully determine potential treatment targets.

摘要

神经母细胞瘤是12个月以下婴儿最常见的癌症,发病率为每10万名儿童中有1例。神经母细胞瘤的临床结果从自发消退到治疗抵抗性进展和/或转移不等,占儿童癌症死亡人数的8-10%。节段性染色体畸变以及 和 扩增是导致不良基因组特征和高危疾病分类的因素之一。在此,我们描述了一名5岁男性,他患有巨大的右肾神经母细胞瘤,伴有肺和肝转移。荧光原位杂交分析表明,在26%的检测细胞中存在>20个 基因5'区域的拷贝。随后的拷贝数评估未证实 扩增,但显示 外显子2-5的增加,与 基因5'区域的拷贝数增加一致。随后的阵列分析显示存在其他不良预后基因组特征,包括17q区域的节段性增加以及12号染色体长臂的扩增,其中 和 均被报道为神经母细胞瘤非典型临床特征患者的不良预后指标。综上所述,本报告说明了仔细解读异常荧光原位杂交结果以及随后使用正交方法来阐明基因组改变的存在对于成功确定潜在治疗靶点的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a00a/8077488/af664d821c74/cro-0014-0585-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a00a/8077488/5af7a2b9249b/cro-0014-0585-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a00a/8077488/fddfa4deaad8/cro-0014-0585-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a00a/8077488/332fd6baa6a9/cro-0014-0585-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a00a/8077488/af664d821c74/cro-0014-0585-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a00a/8077488/5af7a2b9249b/cro-0014-0585-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a00a/8077488/fddfa4deaad8/cro-0014-0585-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a00a/8077488/332fd6baa6a9/cro-0014-0585-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a00a/8077488/af664d821c74/cro-0014-0585-g04.jpg

相似文献

1
5' Amplification in Neuroblastoma: A Case Report.神经母细胞瘤中的5' 扩增:一例报告。
Case Rep Oncol. 2021 Mar 23;14(1):585-591. doi: 10.1159/000512187. eCollection 2021 Jan-Apr.
2
Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.拷贝数异常估计:外显子测序数据与 SNP 微阵列的比较鉴定出神经母细胞瘤中 19q13.2 和 CIC 的纯合缺失。
Int J Oncol. 2016 Mar;48(3):1103-16. doi: 10.3892/ijo.2016.3349. Epub 2016 Jan 19.
3
Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without amplification.节段性染色体畸变是18个月以上3期无扩增神经母细胞瘤患儿预后不良的因素。
Front Oncol. 2023 Feb 14;13:1134772. doi: 10.3389/fonc.2023.1134772. eCollection 2023.
4
Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas.ALK基因的异常拷贝数是神经母细胞瘤中常见的基因改变。
Hum Pathol. 2009 Nov;40(11):1638-42. doi: 10.1016/j.humpath.2009.05.002. Epub 2009 Aug 5.
5
ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.使用三种抗体检测神经母细胞瘤中ALK基因拷贝数增加及免疫组化表达状态
Pediatr Dev Pathol. 2017 Mar-Apr;20(2):133-141. doi: 10.1177/1093526616686445. Epub 2017 Jan 25.
6
Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.17号染色体长臂远端的扩增与神经母细胞瘤的不良预后无关。
Clin Cancer Res. 2003 Oct 15;9(13):4835-40.
7
Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24.17号染色体长臂的获得与神经母细胞瘤的不良预后相关,但不涉及17q24处生长抑素受体2(SSTR2)基因的突变。
Br J Cancer. 1999 Dec;81(8):1402-9. doi: 10.1038/sj.bjc.6692231.
8
Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction.使用实时定量聚合酶链反应检测人类神经母细胞瘤中单拷贝17号染色体的增加。
Mod Pathol. 2003 Dec;16(12):1248-56. doi: 10.1097/01.MP.0000097364.64566.81.
9
MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.MYCN基因的过表达与神经母细胞瘤肿瘤及细胞系中拷贝数增加失衡、核定位改变以及17号染色体长臂基因的过表达相关。
Genes Chromosomes Cancer. 2015 Oct;54(10):616-28. doi: 10.1002/gcc.22273. Epub 2015 Jul 14.
10
Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.对 90 例散发性神经母细胞瘤肿瘤中间变性淋巴瘤激酶 (ALK) 基因的拷贝数状态和突变分析。
Cancer Lett. 2012 Apr 1;317(1):72-7. doi: 10.1016/j.canlet.2011.11.013. Epub 2011 Nov 13.

引用本文的文献

1
Identification of Mutation in Neuroblastoma on the Point of Molecular Heterogeneity.神经母细胞瘤分子异质性研究点的基因突变鉴定。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231211138. doi: 10.1177/15330338231211138.
2
MYCN in Neuroblastoma: "Old Wine into New Wineskins".神经母细胞瘤中的MYCN:“旧瓶装新酒”
Diseases. 2021 Oct 29;9(4):78. doi: 10.3390/diseases9040078.

本文引用的文献

1
Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.神经母细胞瘤患者中 CDK4/MDM2/FRS2 的基因组共扩增与极差的预后和非典型的临床特征相关。
Genes Chromosomes Cancer. 2020 May;59(5):277-285. doi: 10.1002/gcc.22827. Epub 2019 Dec 3.
2
Genetic Predisposition to Neuroblastoma.神经母细胞瘤的遗传易感性
Children (Basel). 2018 Aug 31;5(9):119. doi: 10.3390/children5090119.
3
A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
克唑替尼用于复发或难治性间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤的I/II期研究及克唑替尼用于复发或难治性神经母细胞瘤的I期研究:一项多中心单臂开放标签试验的研究方案
Acta Med Okayama. 2018 Aug;72(4):431-436. doi: 10.18926/AMO/56184.
4
ALK in Neuroblastoma: Biological and Therapeutic Implications.间变性淋巴瘤激酶在神经母细胞瘤中的生物学及治疗意义
Cancers (Basel). 2018 Apr 10;10(4):113. doi: 10.3390/cancers10040113.
5
The ALK receptor in sympathetic neuron development and neuroblastoma.ALK 受体在交感神经元发育和神经母细胞瘤中的作用。
Cell Tissue Res. 2018 May;372(2):325-337. doi: 10.1007/s00441-017-2784-8. Epub 2018 Jan 27.
6
Spontaneous regression of neuroblastoma.神经母细胞瘤的自发消退。
Cell Tissue Res. 2018 May;372(2):277-286. doi: 10.1007/s00441-017-2761-2. Epub 2018 Jan 5.
7
Neuroblastoma treatment in the post-genomic era.后基因组时代的神经母细胞瘤治疗
J Biomed Sci. 2017 Feb 8;24(1):14. doi: 10.1186/s12929-017-0319-y.
8
Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.荧光原位杂交(FISH)和免疫组织化学组合分析揭示了 NSCLC 中 ALK 融合模式的罕见基因组事件,这些事件对克唑替尼治疗有反应。
J Thorac Oncol. 2017 Jan;12(1):94-101. doi: 10.1016/j.jtho.2016.08.145. Epub 2016 Sep 8.
9
The role of the ALK receptor in cancer biology.ALK 受体在癌症生物学中的作用。
Ann Oncol. 2016 Sep;27 Suppl 3:iii4-iii15. doi: 10.1093/annonc/mdw301.
10
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).间变性淋巴瘤激酶(ALK)免疫组化的前瞻性和临床验证:阿来替尼治疗ALK阳性肺癌的I/II期研究(AF-001JP研究)结果
Ann Oncol. 2016 Jan;27(1):185-92. doi: 10.1093/annonc/mdv501. Epub 2015 Oct 20.